Bristol-Myers Squibb (BMY) Tops Q4 EPS by 20c; guides below consensus
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $54.70 --0%
EPS Growth %: +10.3%
Financial Fact:
Marketing, selling and administrative: 1.14B
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +10.3%
Financial Fact:
Marketing, selling and administrative: 1.14B
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.67, $0.20 better than the analyst estimate of $1.47. Revenue for the quarter came in at $12.34 billion versus the consensus estimate of $11.54 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2025 EPS of $6.55-$6.85, versus the consensus of $6.92. Bristol-Myers Squibb sees FY2025 revenue of $45.5 billion, versus the consensus of $46.27 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Fortitude and HeartSciences agree to all-stock merger deal
- Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
